☆ 4.8 Article

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

ONCOGENE (2002)

Journal

ONCOGENE

Volume 21, Issue 56, Pages 8541-8546

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/sj.onc.1206081

Keywords

Bcr-Abl; tyrosine kinase; inhibitor; CML; STI571

Categories

Biochemistry & Molecular Biology Oncology Cell Biology Genetics & Heredity

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.